Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04640142
Other study ID # NORM-01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 4, 2021
Est. completion date June 2025

Study information

Verified date May 2024
Source Octapharma
Contact Patrick Murphy
Phone 866-337-1868
Email ctgov@clinicalresearchmgt.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 2 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age of =2 years and =75 years 2. Documented and confirmed diagnosis of PID as defined by European Society of Immunodeficiencies (ESID) and the Pan American Group for Immune Deficiency (PAGID) and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PID must be recorded. 3. At least 12 weeks of regular treatment before the screening visit (i.e., with a stable dosing interval) with any IVIG, SCIG, or fSCIG, with a stable IgG dose between 200 and 800 mg/kg/month. A stable dose is defined as one that deviates less than ±25% from the mean dose for all infusions within this 12-week period before screening. 4. Trough level of IgG =5 g/L at screening and documentation of an IgG trough level of =5 g/L at least once within the previous 12 weeks. 5. Freely given written informed consent from adult patients or freely given written informed consent from the patient's parent(s)/legal guardian(s) and written informed assent from paediatric or adolescent patients in accordance with the applicable regulatory requirements, before any study-specific procedure takes place. 6. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study. Exclusion Criteria: 1. Any acute infection requiring IV antibiotic treatment within 2 weeks before the screening visit or during the screening period, or any SBI within the 3 months prior to the screening visit or during the screening period. 2. The patient has isolated specific antibody deficiency disorder, isolated IgG subclass deficiency, or transient hypogammaglobulinaemia of infancy. 3. Current medical condition or history of condition known to cause secondary immune deficiency, for example, chronic lymphocytic leukaemia, lymphoma, multiple myeloma, or chronic or recurrent neutropenia (absolute neutrophil count <1000/µL). 4. Known history of ADRs to IgA contained in other products. 5. Body mass index >40 kg/m2. 6. Exposure to blood or any blood product or plasma derivative other than IgG for PID within 3 months before the first infusion of Newnorm. 7. History of or ongoing severe hypersensitivity, e.g., anaphylaxis or severe systemic response, or persistent reactions to blood or plasma-derived products, or to any component of Newnorm (such as glycine). 8. Severe liver dysfunction (alanine aminotransferase [ALT] >3 times the upper limit of normal for the expected normal range for the testing laboratory) at screening. 9. Known protein-losing enteropathies or proteinuria (known urinary protein loss of >1 g/24 h, or dipstick proteinuria of =3+). 10. Moderate to severe renal dysfunction (per investigator discretion based on estimated glomerular filtration rate [eGFR] =44 mL/min/1.73 m2, as defined by KDIGO Clinical Practice Guideline) or predisposition to acute renal failure (e.g., any degree of pre-existing renal dysfunction in presence of additional acute renal failure risk factors, e.g. routine treatment with known nephrotoxic drugs). 11. Uncontrolled diabetes mellitus (HbA1c > 7% / >53 mmol/mol). 12. Uncontrolled arterial hypertension (systolic blood pressure of = 130 mmHg for the subject under 13 years of age, = 140 mmHg for subject 13 to 17 years of age, and > 160 mmHg for adults). 13. Dysrhythmia/Tachycardia (resting heart rate > 100 bpm for adults/adolescents and > 120 bpm for children) and symptomatic bradycardia (resting heart rate < 60 bpm for adults, < 50 bpm for adolescents, and < 75 bpm for children in presence of symptoms e.g., low blood pressure, abnormal rhythm, chest discomfort, shortness of breath). Physiological sinus bradycardia in physically active adults/children/athletes is NOT an exclusion criterion). 14. The subject has a history of or current diagnosis of deep venous thrombosis or thromboembolism (e.g. myocardial infarction, cerebrovascular accident, or transient ischemic attack); history refers to an incident in the year prior to screening or 2 episodes over lifetime. 15. The subject is currently receiving anti-coagulation therapy which would make SC administration inadvisable (vitamin K antagonist, nonvitamin K antagonist oral anticoagulants [e.g. dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa], parenteral anticoagulants [e.g. fondaparinux]). 16. Treatment with oral or parenteral steroids either 1. at daily doses >0.3 mg/kg of prednisone (or equivalent) within the last 12 weeks before screening or 2. bolus treatment of a daily dose greater than 1 mg/kg of prednisone (or equivalent) for longer than 10 days within the last 12 weeks before screening. Courses of corticosteroids (intermittent) of not more than 10 days would not exclude a patient. Inhaled or topical corticosteroids are allowed. 17. Treatment with systemic immunosuppressants including chemotherapeutic agents 1 year before screening or immunomodulatory drugs 12 weeks before the screening visit. 18. Live viral vaccination (such as measles, rubella, mumps, or varicella) within 1 month before the first infusion of Newnorm, during the study period, and within 3 months after last infusion of Newnorm. Note: Seasonal inactivated (killed) influenza vaccines (incl. H1N1) are allowed. COVID vaccines (mRNA vaccine and a non-replicating viral vector vaccine) are allowed. 19. Treatment with any investigational medicinal product (IMP) within 3 months before the screening visit. 20. Presence of any condition likely to interfere with the evaluation of Newnorm or with the compliant conduct of the study. 21. Known or suspected abuse of alcohol, drugs, and/or psychotropic agents within 12 months before screening. 22. Known human immunodeficiency virus (HIV)-1/2, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or positive for HIV-1/2, HBV, or HCV at screening. 23. Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (refer to protocol Section 7.4.10.b) while on study and for 30 days following the last dose of study drug. 24. Men who are unwilling to use birth control to prevent pregnancy for the duration of the study (unless the female partner

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Newnorm
Newnorm is a 20% human normal immunoglobulin for SC infusion.

Locations

Country Name City State
Germany Octapharma Research Site Leipzig
Germany Octapharma Research Site Munich
Hungary Octapharma Research Site Budapest
Hungary Octapharma Research Site Debrecen
Italy Octapharma Research Site Napoli
Italy Octapharma Research Site Roma
Italy Octapharma Research Site Roma
Italy Octapharma Research Site Roma
Italy Octapharma Research Site Treviso
Poland Octapharma Research Site Kraków
Poland Octapharma Research Site Warsaw
Slovakia Octapharma Research Site Bratislava
Slovakia Octapharma Research Site Martin
Ukraine Octapharma Research Site Kyiv
Ukraine Octapharma Research Site Lviv
Ukraine Octapharma Research Site Lviv
United States Octapharma Research Site Chicago Illinois
United States Octapharma Research Site Irvine California
United States Octapharma Research Site Kansas City Missouri
United States Octapharma Research Site Los Angeles California
United States Octapharma Research Site Louisville Kentucky
United States Octapharma Research Site Omaha Nebraska
United States Octapharma Research Site Overland Park Kansas
United States Octapharma Research Site Saint Petersburg Florida
United States Octapharma Research Site White Marsh Maryland

Sponsors (1)

Lead Sponsor Collaborator
Octapharma

Countries where clinical trial is conducted

United States,  Germany,  Hungary,  Italy,  Poland,  Slovakia,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Serious Bacterial Infections Rate of SBIs (defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment. 52 weeks
Primary Average total IgG concentration Average total IgG concentration (Cav) on steadystate dosing. 16 weeks
Secondary Infections of any type of seriousness Infections of any type or seriousness (including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, acute bronchitis, infectious diarrhoea, etc) (total and by category, annual rate) 52 weeks
Secondary Time to resolution of infections Time to resolution of infections 52 weeks
Secondary Use of antibiotics Use of antibiotics (number of days on antibiotics and annual rate of treatment episodes) characterised as therapeutic or prophylactic use 52 weeks
Secondary Hospitalisations due to infection Hospitalisations due to infection (number of days and annual rate) 52 weeks
Secondary Episodes of fever Episodes of fever 52 weeks
Secondary Days lost from work, school, kindergarten, or day care due to infection Days lost from work, school, kindergarten, or day care due to infection 52 weeks
Secondary Child Health Questionnaire-Parent Form Child Health Questionnaire-Parent Form (CHQPF50) for patients <14 years 52 weeks
Secondary SF-36 Health Survey SF-36 Health Survey for patients = 14 of age 52 weeks
Secondary Non-compartmental PK analyses of all available PK profiles (IVIG and SCIG) Total IgG, IgG subclasses (IgG1, IgG2, IgG3, and IgG4), and antigen specific antibodies against Haemophilus influenzae B (capsular polysaccharide), Streptococcus pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), cytomegalovirus (CMV), tetanus, and measles 16 weeks
Secondary IgG Levels Trough and peak levels of total IgG and IgG subclasses for weekly Newnorm relative to 3- or 4-weekly IVIG dosing 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05321407 - COVID-19 Vaccine Responses in PIDD Subjects
Completed NCT01199705 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Phase 3
Recruiting NCT05070455 - An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) Phase 4
Recruiting NCT03836690 - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase 1
Completed NCT01461018 - Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study) Phase 3
Completed NCT04581460 - Primitive Immunodeficiency and Pregnancy
Recruiting NCT05476653 - A Prospective Monocentric Study to Assess the Concordance of Lung MRI Compared to Chest CT Scan to Assess the Extent and Severity of Bronchial and Parenchymal Pulmonary Lesions in Adult Patients With Primary Immune Deficiency (PID) . N/A
Completed NCT00419341 - Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy Phase 3
Active, not recruiting NCT02868333 - Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood N/A
Completed NCT01166074 - Retrospective Chart Review of Subcutaneous IgG Use in Infants N/A
Recruiting NCT05932316 - Evaluating Bronchodilator Response in Patients With Bronchiectasis N/A
Recruiting NCT04784364 - Biologics And Clinical Immunology Cohort at Sinai
Completed NCT06014463 - Evaluation of Adult Patients With Immunodeficiency Within the Scope of the ICF
Recruiting NCT04459689 - COVID-19 in PID Survey
Completed NCT02711228 - Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Phase 4
Recruiting NCT04919018 - Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
Completed NCT00719680 - Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) Phase 3
Terminated NCT00023504 - Antibody Production in Immune Disorders Phase 4
Recruiting NCT00246857 - Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Recruiting NCT04565015 - Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency Phase 3